Title: Treatment measures in rheumatology: An overview of the use of targeted biologic therapies
Authors: Loughlin, Ciara
Abstract: There have been many exciting developments in rheumatology
over the last two decades. A greater understanding
of the functioning of the immune system in
rheumatologic disorders has resulted in the development
of targeted biologic therapies for patients.1
Biologic therapies represent a new kind of treatment for
patients with a wide range of rheumatologic conditions such
as rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing
spondylitis (AS) and systemic lupus erythematosus (SLE).
Traditional therapies such as methotrexate, salazopyrine,
plaquenil and arava are still very much part of the patients
prescribed program with methotrexate remaining the first line
treatment used in the management of inflammatory arthritis.
However the advances in molecular biology have led to an array
of new treatment approaches to inflammatory arthritis.2
↧